Amneal Pharmaceuticals, Inc. (NYSE:AMRX) went up by 2.13% from its latest closing price when compared to the 1-year high value of $19.00 and move down -394.79%, while AMRX stocks collected +13.61% of gains with the last five trading sessions. Press Release reported 7 hours ago that Amneal Announces the Approval and Launch of Generic Revatio(R) for Oral Suspension and Generic Amicar(R) Tablets

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Worth an Investment?

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) The 36 Months beta value for AMRX stocks is at 1.47, while of the analysts out of 0 who provided ratings for Amneal Pharmaceuticals, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $3.75 which is -$0.09 below current price. AMRX currently has a short float of 6.88% and public float of 82.41M with average trading volume of 1.71M shares.

AMRX Market Performance

AMRX stocks went up by 23.08% for the week, with the monthly jump of 24.68% and a quarterly performance of 49.42%, while its annual performance rate touched -79.65%. The simple moving average for the period of the last 20 days is 26.77% for AMRX stocks with the simple moving average of -45.19% for the last 200 days.

Analysts’ Opinion on Amneal Pharmaceuticals, Inc. (NYSE:AMRX)

Many brokerage firms have already submitted their reports for AMRX stocks, with JP Morgan repeating the rating for AMRX shares by setting it to “Underweight”. The predicted price for AMRX socks in the upcoming period according to JP Morgan is $90 based on the research report published on November 12, 2019.

SVB Leerink, on the other hand, stated in their research note that they expect to see AMRX stock at the price of $90. The rating they have provided for AMRX stocks is “Mkt Perform” according to the report published on November 7, 2019.

SVB Leerink gave “ Outperform” rating to AMRX stocks, setting the target price at $5 in the report published on July 22, 2019.

AMRX Stocks 25.88% Far from 50 Day Moving Average

After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, Amneal Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -79.79% of loss for the given period.

The stock volatility was left at 8.83%, however, within the period of a single month, the volatility rate increased by 12.98%, while the shares surge at the distance of +11.95% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +14.97% upper at the present time.

In the course of the last 5 trading sessions, AMRX went up by +13.61%, which changed the moving average for the period of 200 days to the total of -72.05% of losses for the stock in comparison to the 20-day moving average settled at $3.05. In addition, Amneal Pharmaceuticals, Inc. saw -71.62% in overturn over the period of a single year with a tendency to cut further losses.

AMRX Stock Fundamentals

The current profitability levels are settled at -2.59 for the present operating margin and +33.69 for gross margin. The net margin for Amneal Pharmaceuticals, Inc. stands at -60.49. Total capital return value is set at -38.63, while invested capital returns managed to touch -39.20. Equity return holds the value -81.80%, with -8.10% for asset returns.

Based on Amneal Pharmaceuticals, Inc. (AMRX), the company’s capital structure generated 420.60 points for debt to equity in total, while total debt to capital is set at the value of 80.79. Total debt to assets is settled at the value of 58.27 with long-term debt to equity ratio rests at -0.37 and long-term debt to capital is 411.07.

EBITDA value lies at +3.16 M with total debt to EBITDA carrying the value of 9.09. The value for Enterprise to Sales is 2.52 with debt to enterprise value settled at 0.44. The receivables turnover for Amneal Pharmaceuticals, Inc. is 2.77 with the total asset turnover at the value of 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.96.